Front Street Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-1,648
Closed -$235K 69
2024
Q2
$235K Hold
1,648
0.05% 65
2024
Q1
$212K Hold
1,648
0.04% 67
2023
Q4
$170K Hold
1,648
0.03% 70
2023
Q3
$150K Buy
+1,648
New +$145K 0.03% 69

Other funds holding NVO

Front Street Capital Management's NVO Position: Q3 2024 in Review

Front Street Capital Management sold out of Novo Nordisk (NVO) in Q3 2024, closing a stake of 1,648 shares — an estimated $235K sold.

Front Street Capital Management first reported a position in NVO in Q3 2023 and held it in 4 quarters. The position peaked at $235K in Q2 2024. 1,784 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

  • Front Street Capital Management reported no remaining Novo Nordisk position as of Q3 2024 after selling out during the quarter.
  • Front Street Capital Management sold 1,648 Novo Nordisk shares in Q3 2024, an estimated $235K.
  • Front Street Capital Management first reported a position in Novo Nordisk in Q3 2023 and held it in 4 quarters.
  • Front Street Capital Management's Novo Nordisk position peaked at $235K in Q2 2024.
  • 1,784 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on Front Street Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.